Medtronic’s BioGlide catheter issued class I recall
This article was originally published in Clinica
The US FDA has given Medtronic’s voluntary recall of its BioGlide ventricular snap shunt catheter a class I classification. The recall, which was initiated by the company in February, was triggered by nine reports of disconnected catheters that required revision surgery. In its recall notice, the FDA said that the action applied to 3,000 BioGlide catheters in the US, Ireland and Australia, and, as of March 18, Medtronic had completed contact with all users of the devices. The FDA said that there have been no reports of serious patient injury or death because of the faults.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals